Cravath Publishes Winter 2026 Issue of Alumni Journal
Sarah W.
Colangelo
Of Counsel, Executive Compensation and Benefits
Sarah W. Colangelo focuses her practice on executive compensation and employee benefit matters, principally in connection with mergers and acquisitions, securities offerings and other corporate transactions.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Education
-
J.D., 2014, Georgetown University Law CenterOrder of the Coif, magna cum laude
-
B.A., 2007, Duke UniversityPhi Beta Kappa, summa cum laude
Admitted In
- New York
Deals & Cases
February 24, 2026
ADT’s Acquisition of Origin
On February 24, 2026, ADT, a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., announced it has acquired Origin Wireless, Inc. (“Origin”), bringing Origin’s AI sensing platform and related intellectual property into the ADT ecosystem. The purchase price for the transaction was $170 million in cash, subject to customary purchase price adjustments. Cravath is representing ADT in connection with the transaction.
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
November 03, 2025
Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark
On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.
Deals & Cases
October 02, 2025
Occidental’s $9.7 Billion Sale of OxyChem to Berkshire Hathaway
On October 2, 2025, Occidental, an international energy company, and Berkshire Hathaway announced a definitive agreement for Berkshire Hathaway to acquire Occidental’s chemical business, OxyChem, in an all‑cash transaction for $9.7 billion, subject to customary purchase price adjustments. Cravath is representing Occidental in connection with the transaction.
Deals & Cases
October 01, 2025
Corteva’s Planned Separation into Two Public Companies
On October 1, 2025, global agricultural technology leader Corteva announced that its Board of Directors has unanimously approved a plan to separate the company into two independent, publicly traded companies, one comprising its current Crop Protection business (“New Corteva”) and the other comprising its current Seed business (“SpinCo”). 2025 net sales attributable to New Corteva are estimated to total $7.8 billion, representing 44% of net sales for Corteva; 2025 net sales attributable to SpinCo are estimated to total $9.9 billion, representing 56% of net sales for Corteva. The separation is expected to be effected through a spin‑off of SpinCo that is intended to qualify as a tax‑free transaction for U.S. federal tax purposes to Corteva shareholders. Cravath is representing Corteva in connection with the transaction.
Sarah W. Colangelo focuses her practice on executive compensation and employee benefit matters, principally in connection with mergers and acquisitions, securities offerings and other corporate transactions.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Education
-
J.D., 2014, Georgetown University Law CenterOrder of the Coif, magna cum laude
-
B.A., 2007, Duke UniversityPhi Beta Kappa, summa cum laude
Admitted In
- New York
Deals & Cases
February 24, 2026
ADT’s Acquisition of Origin
On February 24, 2026, ADT, a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., announced it has acquired Origin Wireless, Inc. (“Origin”), bringing Origin’s AI sensing platform and related intellectual property into the ADT ecosystem. The purchase price for the transaction was $170 million in cash, subject to customary purchase price adjustments. Cravath is representing ADT in connection with the transaction.
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
November 03, 2025
Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark
On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.
Deals & Cases
October 02, 2025
Occidental’s $9.7 Billion Sale of OxyChem to Berkshire Hathaway
On October 2, 2025, Occidental, an international energy company, and Berkshire Hathaway announced a definitive agreement for Berkshire Hathaway to acquire Occidental’s chemical business, OxyChem, in an all‑cash transaction for $9.7 billion, subject to customary purchase price adjustments. Cravath is representing Occidental in connection with the transaction.
Deals & Cases
October 01, 2025
Corteva’s Planned Separation into Two Public Companies
On October 1, 2025, global agricultural technology leader Corteva announced that its Board of Directors has unanimously approved a plan to separate the company into two independent, publicly traded companies, one comprising its current Crop Protection business (“New Corteva”) and the other comprising its current Seed business (“SpinCo”). 2025 net sales attributable to New Corteva are estimated to total $7.8 billion, representing 44% of net sales for Corteva; 2025 net sales attributable to SpinCo are estimated to total $9.9 billion, representing 56% of net sales for Corteva. The separation is expected to be effected through a spin‑off of SpinCo that is intended to qualify as a tax‑free transaction for U.S. federal tax purposes to Corteva shareholders. Cravath is representing Corteva in connection with the transaction.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.